Join

Compare · NVCR vs WST

NVCR vs WST

Side-by-side comparison of NovoCure Limited (NVCR) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVCR and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • WST is the larger of the two at $23.64B, about 11.8x NVCR ($2.00B).
  • Over the past year, NVCR is down 6.1% and WST is up 47.1% - WST leads by 53.2 points.
  • NVCR has been more active in the news (18 items in the past 4 weeks vs 5 for WST).
  • NVCR has more recent analyst coverage (25 ratings vs 17 for WST).
PerformanceNVCR-6.14%WST+47.10%
2025-06-10+0.00%2026-06-09
MetricNVCRWST
Company
NovoCure Limited
West Pharmaceutical Services Inc.
Price
$17.26+2.49%
$334.67+4.58%
Market cap
$2.00B
$23.64B
1M return
-3.47%
+2.67%
1Y return
-6.14%
+47.10%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NASDAQ
NYSE
IPO
2015
News (4w)
18
5
Recent ratings
25
17
NVCR

NovoCure Limited

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.

WST

West Pharmaceutical Services Inc.

West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

Latest NVCR

Latest WST